Yawei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yawei Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Chaojie Yang
Infectious Disease Control and Prevention Department Chinese PLA Center for Disease Control and Prevention Beijing China
1 shared publicationHongbin Song
College of Public Health Zhengzhou University Zhengzhou China
1 shared publicationLigui Wang
Infectious Disease Control and Prevention Department Chinese PLA Center for Disease Control and Prevention Beijing China
1 shared publicationMin Wang
Infectious Disease Control and Prevention Department Chinese PLA Center for Disease Control and Prevention Beijing China
1 shared publicationRenlong Bao
Infectious Disease Control and Prevention Department Chinese PLA Center for Disease Control and Prevention Beijing China
1 shared publicationShaofu Qiu
Infectious Disease Control and Prevention Department Chinese PLA Center for Disease Control and Prevention Beijing China
1 shared publication
Latest Publications
- Open Access
- 14 August 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (8) , e29026
A novel humanized tri‐receptor transgenic mouse model of HAdV infection and pathogenesis
Human adenovirus (HAdV) is a highly virulent respiratory pathogen that poses clinical challenges in terms of diagnostics and treatment. Currently, no effective therapeutic drugs or prophylactic vaccines are available for HAdV infections. One factor contributing to this deficiency is that existing animal models, including wild‐type and single‐receptor transgenic mice, are unsuitable for HAdV proliferation and pathology testing. In this study, a tri‐receptor transgenic mouse model expressing the three best‐characterized human cellular receptors for HAdV (hCAR, hCD46, and hDSG2) was generated and validated via analysis of transgene insertion, receptor mRNA expression, and protein abundance distribution. Following HAdV‐7 infection, the tri‐receptor mice exhibited high transcription levels at the early and late stages of the HAdV gene, as well as viral protein expression. Furthermore, the tri‐receptor mice infected with HAdV exhibited dysregulated cytokine responses and multiple tissue lesions. This transgenic mouse model represents human HAdV infection and pathogenesis with more accuracy than any other reported animal model. As such, this model facilitates the comprehensive investigation of HAdV pathogenesis as well as the evaluation of potential vaccines and therapeutic modalities for HAdV.
- 14 August 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (8) , e29026
Open AccessA novel humanized tri‐receptor transgenic mouse model of HAdV infection and pathogenesis
Human adenovirus (HAdV) is a highly virulent respiratory pathogen that poses clinical challenges in terms of diagnostics and treatment. Currently, no effective therapeutic drugs or prophylactic vaccines are available for HAdV infections. One factor contributing to this deficiency is that existing animal models, including wild‐type and single‐receptor transgenic mice, are unsuitable for HAdV proliferation and pathology testing. In this study, a tri‐receptor transgenic mouse model expressing the three best‐characterized human cellular receptors for HAdV (hCAR, hCD46, and hDSG2) was generated and validated via analysis of transgene insertion, receptor mRNA expression, and protein abundance distribution. Following HAdV‐7 infection, the tri‐receptor mice exhibited high transcription levels at the early and late stages of the HAdV gene, as well as viral protein expression. Furthermore, the tri‐receptor mice infected with HAdV exhibited dysregulated cytokine responses and multiple tissue lesions. This transgenic mouse model represents human HAdV infection and pathogenesis with more accuracy than any other reported animal model. As such, this model facilitates the comprehensive investigation of HAdV pathogenesis as well as the evaluation of potential vaccines and therapeutic modalities for HAdV.